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Abstract
Background In palliative care patients, fatigue can be severely debilitating and is often not counteracted with rest, thereby
impacting daily activity and quality of life. Further complicating issues are the multidimensionality, subjective nature and lack
of a consensus deﬁnition of fatigue. The review aimed to evaluate the efﬁcacy of pharmacological treatments for fatigue in pal-
liative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases.
Methods We considered randomized controlled trials concerning adult palliative care with a focus on pharmacological treat-
ment of fatigue compared with placebo, application of two drugs, usual care or a non-pharmacological intervention. The pri-
mary outcome had to be non-speciﬁc fatigue (or related terms such as asthenia). We searched the CENTRAL, MEDLINE,
PsycINFO and EMBASE, and a selection of cancer journals up to 28 April 2014. Two review authors independently assessed
trial quality and extracted the data.
Results We screened 1645 publications of which 45 met the inclusion criteria. In total, we analysed data from 18 drugs and
4696 participants. There was a very high degree of statistical and clinical heterogeneity in the trials. Meta-analysis of data was
possible for modaﬁnil, pemoline, and methylphenidate.
Conclusions Due to the limited evidence, we cannot recommend a speciﬁc drug for the treatment of fatigue in palliative
care patients. Some drugs, which may be beneﬁcial for the treatment of fatigue associated with palliative care such as aman-
tadine, methylphenidate, and modaﬁnil, should be further researched.
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Introduction
Fatigue is a common symptom in palliative care patients, and
virtually, every intervention used to treat cancer, as well as
the primary disease itself, may cause or contribute to fatigue.
In a study of 1000 patients in an American palliative care pro-
gramme, fatigue, weakness, and lack of energy were three of
the ﬁve most frequently reported symptoms with a preva-
lence of 84%, 66%, and 61%, respectively.1 Fatigue is also
commonly reported in non-cancer patients with progressive
life-threatening diseases, such as multiple sclerosis and .
amyotrophic lateral sclerosis,2 chronic obstructive pulmo-
nary disease,3 heart failure,4 HIV,5 as well as chronic heart,
kidney, or lung diseases.6,7 Several drugs, such as the new
anti-neoplastic therapies, or drugs regularly used in pallia-
tive care have sedative properties, for example, opioid anal-
gesics, benzodiazepines, antidepressants, or anticonvulsants
can cause fatigue.8
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The pathophysiology of fatigue in palliative care patients is
not fully understood. ‘Primary fatigue’ has been said to be
related to the high cytokine load. Disease-related symptoms,
such as sleep disturbances, may also account for fatigue and
may be termed ‘secondary fatigue’. There are several deﬁni-
tions of fatigue. For this Cochrane review, we selected the def-
inition of the European Association of Palliative Care: ‘Fatigue is
a subjective feeling of tiredness, weakness, or lack of energy’.8
Assessment of fatigue will depend on subjective self-
assessment by the patient, substituted by caregiver or medical
staff estimations only where self assessment is not possible.
Single-item scales have been proposed, and a multitude of
checklists and questionnaires with multiple dimensions have
been validated.9 It is possible that a number of hindrances
such as lack of consensus on the deﬁnition of fatigue or on
signiﬁcant cut-off levels of evaluation instruments limited
structured approach with assessment and treatment steps
have led to underestimation and undertreatment fatigue.
If possible, a causative treatment approach should be
addressed. Most patients will require symptomatic treatment
of fatigue with pharmacological and non-pharmacological ther-
apies. Some studies10,11 have examined the role of non-drug
treatments for cancer-related fatigue, such as patient educa-
tion with provision of information on fatigue and its treatment,
keeping a diary, energy expenditure planning, and physical ex-
ercise. On the other hand, there is a growing body of evidence
that gives examples of effective pharmacological treatments
for fatigue.12–14 Several recent systematic reviews15–17 have
covered some drugs used to treat fatigue in cancer patients.
This paper provides an executive summary of a recent
Cochrane Collaboration systematic review,18 which synthesizes
evidence for the evaluation of the efﬁcacy of pharmacological
treatments for fatigue in palliative care, with a focus on patients
at an advanced stage of disease, including patients with cancer
and other chronic diseases. The review updated the original
review,19 ‘Pharmacological treatments for fatigue associated
with palliative care’ and also incorporated the review ‘Drug
therapy for the management of cancer-related fatigue’.16
Materials and methods
Eligibility criteria
Criteria for review entry were randomized controlled trials with
focus on pharmacological treatment involving adults (≥18years,
both sexes), suffering fatigue in palliative care or in terminal
illness. Participants could receive anti-cancer treatment.
Outcome measures
Patient-reported fatigue and the improvement of fatigue
were the primary outcomes of this review, while the
secondary outcomes included asthenia, weakness, tiredness,
exhaustion, and treatment-related burden.
Search strategy
We re-engineered the search strategy (ﬁlter) of the previous
review by Peuckmann-Post et al.19 to facilitate the combina-
tion with another review by Minton et al.16 To identify studies
for inclusion in this updated review, we developed a detailed
search strategy for each electronic database and other re-
sources. To validate the search strategy, we selected sentinel
studies.20,21 The following electronic databases were searched
from their inception until 28 April 2014 CENTRAL, MEDLINE
(Ovid), PsycINFO (Ovid), and EMBASE. Additional information
was obtained from standard textbooks on palliative medicine,
unpublished literature through searches of conference pro-
ceedings and also from experts in the ﬁeld of palliative care.
Data collection and analysis
Two review authors extracted the data (M.M. and M. C.)
using a standard data extraction form and reviewed the data
from the included studies. Two other authors (L. R. and H. C.)
cross-checked and sub-sampled the data. We contacted the
original investigators when dealing with the missing data.
Two authors (M.M. and M. C.) independently assessed risk
of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions
and adapted from those used by the Cochrane Pregnancy
and Childbirth Group, with any disagreements resolved by
discussion or by involving other review authors (L. R. and H.C.).
Subgroup analysis was performed for dealing with following
different criteria; type of drug, type of disease, and type of as-
sessment tools.
Results
We identiﬁed 1645 publications in the search. After we re-
moved 186 duplicate studies, we retrieved articles against
the inclusion criteria and found 45 studies, which met the in-
clusion criteria (Figure 1). In total, we analysed data from
18 drugs, nine type of disease, and 4696 participants. Only
two21,22 of the treatment groups in this review were large
enough to give a low risk of bias (200 participants or more
per treatment arm). Most studies reported some beneﬁt of
the active treatment. In general, adverse reactions were mild
and had little or no impact.
We used studies investigating pemoline and modaﬁnil in
participants with multiple sclerosis-associated fatigue and
methylphenidate in participants suffering from cancer and fa-
tigue for meta-analysis. However, the US Food and Drug
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Administration (FDA) has decided to withdraw pemoline
products (marketed as Cylert) because of the risk of liver tox-
icity, which outweighs the beneﬁts of the drug.
Methylphenidate in cancer
Meta-analysis was performed for two studies,23,24 which
used the Functional Assessment for Chronic Illness Therapy
- Fatigue as the assessment tool in fatigue, comparing
methylphenidate with placebo. The studies showed a
slightly superior effect of methylphenidate compared with
placebo (standardized mean difference 0.49, 95% conﬁ-
dence interval 0.15 to 0.83; Figure 2).
Modaﬁnil in multiple sclerosis
Modaﬁnil was tested in 115 patients with multiple sclerosis,25
but failed to demonstrate the superiority of modaﬁnil vs.
placebo. Another recent study of 21 patients with multiple
sclerosis showed positive effect of modaﬁnil.2 However, this
result must be interpreted with caution because of the small
participant numbers. Meta-analysis of these two studies also
failed to demonstrate a signiﬁcant effect, with a standardized
mean difference of 0.14 (Figure 3).
Discussion
The aim of the Cochrane review18 was to evaluate the efﬁ-
cacy of pharmacological treatments for fatigue in palliative
care, with a focus on patients at an advanced stage of dis-
ease, including patients with cancer and other chronic
diseases.
Our search strategy allowed us to identify all relevant stud-
ies. We identiﬁed 45 studies for inclusion, with a wide range
of underlying diseases and drug interventions. Treatment
results pointed to weak and inconclusive evidence for the
efﬁcacy of amantadine, pemoline, and modaﬁnil in multiple
sclerosis and for carnitine and donepezil in cancer-related
fatigue. Meta-analysis shows an estimated superior effect
for methylphenidate in cancer-related fatigue, but not for
modaﬁnil in multiple sclerosis. Further studies about the efﬁ-
cacy and safety of potential medicines for fatigue treatment
such as acetylsalicylic acid, mistletoe extract, megestrol
acetate, and medroxyprogesterone acetate are needed.
Figure 2 Forest plot of comparison of methylphenidate vs. placebo in cancer: Functional Assessment for Chronic Illness Therapy - Fatigue score
change.18
Figure 1 Study ﬂow diagram.18
Figure 3 Forest plot of comparison of modaﬁnil in cancer.18
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Many of the included studies involved only a small num-
ber of participants and did not follow a consistent research
methodology. In some cases, the investigated population
was very heterogeneous, and any outcome may have been
associated with depression, making it difﬁcult to distinguish
from primary fatigue. These limitations made it difﬁcult to
compare the methodological quality across the studies.
There are many possible causes of secondary fatigue.
Unfortunately, little evidence from randomized trials is
available on the efﬁcacy of these treatments. In clinical
practice, any potential cause for secondary fatigue should
be treated.
The results of the literature search indicate that recent
research interest focuses on modaﬁnil, which seems a
promising agent to diminish fatigue for palliative care
patients. This may be an interesting perspective for
the future.
Conclusions
There is insufﬁcient evidence to support the use of a speciﬁc
medicine to treat fatigue in palliative care patients. In this
regards, amantadine showed the promised beneﬁt in patients
with multiple sclerosis with fatigue and methylphenidate in
patients with cancer-related fatigue. Further trials are
needed for several medicines, which were used in some stud-
ies with positive results such as dexamethasone, methylpred-
nisolone, acetylsalicylic acid, armodaﬁnil, amantadine, and
L-carnitine. To enhance the interpretation and generalization
of ﬁndings from relevant study populations, randomized con-
trolled trials with larger participant number are required.
Consensus is needed regarding fatigue deﬁnition and out-
come parameters for clinical trials.
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